H
Hyeon-Cheol Gwon
Researcher at Samsung Medical Center
Publications - 256
Citations - 6168
Hyeon-Cheol Gwon is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 37, co-authored 256 publications receiving 4884 citations. Previous affiliations of Hyeon-Cheol Gwon include Sungkyunkwan University & Samsung.
Papers
More filters
Journal ArticleDOI
Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease
Ki Bae Seung,Duk-Woo Park,Young-Hak Kim,Seung-Whan Lee,Cheol Whan Lee,Myeong Ki Hong,Seong-Wook Park,Sung-Cheol Yun,Hyeon-Cheol Gwon,Myung Ho Jeong,Yangsoo Jang,Hyo-Soo Kim,Pum Joon Kim,In Whan Seong,Hun Sik Park,Taehoon Ahn,In-Ho Chae,Seung-Jea Tahk,Wook-Sung Chung,Seung-Jung Park +19 more
TL;DR: In a cohort of patients with unprotected left main coronary artery disease, there was no significant difference in rates of death or of the composite end point of death, Q-wave myocardial infarction, or stroke between patients receiving stents and those undergoing CABG, but stenting, even with drug-eluting stents, was associated with higher rates of target-vessel revascularization than was CABGs.
Journal ArticleDOI
Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: A comparison with conventional cardiopulmonary resuscitation*
Tae Gun Shin,Jin-Ho Choi,Ik Joon Jo,Min Seob Sim,Hyoung Gon Song,Yeon Kwon Jeong,Y.B. Song,Joo-Yong Hahn,Seung-Hyuk Choi,Hyeon-Cheol Gwon,Eun-Seok Jeon,Kiick Sung,Wook Sung Kim,Young Tak Lee +13 more
TL;DR: Extracorporeal cardiopulmonary resuscitation showed a survival benefit over conventional cardiopulent resuscitation in patients who received cardiopULmonary resuscitations for >10 mins after witnessed inhospital arrest, especially in cases with cardiac origins.
Journal ArticleDOI
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Joo-Yong Hahn,Young Bin Song,Ju-Hyeon Oh,Deok Kyu Cho,Jin Bae Lee,Joon-Hyung Doh,Sang-hyun Kim,Jin-Ok Jeong,Jang Ho Bae,Byung Ok Kim,Jang Hyun Cho,Il-Woo Suh,Doo-Il Kim,Hoon Ki Park,Jong-Seon Park,Woong Gil Choi,Wang Soo Lee,Jihoon Kim,Ki Hong Choi,Taek Kyu Park,Joo Myung Lee,Jeong Hoon Yang,Jin-Ho Choi,Seung-Hyuk Choi,Hyeon-Cheol Gwon,Jong-Young Lee,Hun Sik Park,Jin-Yong Hwang,Seung Ho Hur,Seung-Woon Rha,Sang Cheol Cho,Won You Kang,Seong-Hoon Lim,Moo Hyun Kim,Kwang Soo Cha,Rak Kyung Choi,In-Ho Chae,Woo Jin Jang,Yong Hawn Park,Woo Jung Chun,Jae Woong Choi,Myung Ho Jeong,Seung Ho Kang,Kyung-Ju Ahn +43 more
TL;DR: This trial aimed to investigate whether a 6-month duration of DAPT would be non-inferior to the conventional 12-month or longer duration ofDAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Journal ArticleDOI
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
Davide Capodanno,Roxana Mehran,Marco Valgimigli,Usman Baber,Stephan Windecker,Pascal Vranckx,George Dangas,Fabiana Rollini,Takeshi Kimura,Jean-Philippe Collet,C. Michael Gibson,Philippe Gabriel Steg,Renato D. Lopes,Hyeon-Cheol Gwon,Robert F. Storey,Francesco Franchi,Deepak L. Bhatt,Patrick W. Serruys,Dominick J. Angiolillo +18 more
TL;DR: The principles guiding the role of acetylsalicylic acid (aspirin)-free strategies in the prevention and management of cardiovascular disease, along with their implications for clinical trial design and development are discussed.
Journal ArticleDOI
Long-term survival benefit of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation.
Woo Jin Jang,Jeong Hoon Yang,Seung-Hyuk Choi,Young Bin Song,Joo-Yong Hahn,Jin-Ho Choi,Wook Sung Kim,Young Tak Lee,Hyeon-Cheol Gwon +8 more
TL;DR: In patients with coronary CTO and well-developed collateral circulation, aggressive revascularization may reduce the risk of cardiac mortality and MACE.